tegafur-gimeracil-oteracil potassium
Trials 24
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04410887 | Dec 2020 → Dec 2021 | gastric cancer | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT06422858 | May 2024 → Dec 2025 | esophageal squamous cell carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06238167 | Apr 2024 → Dec 2026 expected | gastric cancer | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05960955 | Nov 2023 → Nov 2024 overdue | gastroesophageal adenocarcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 2 | NCT05216237 | Feb 2022 → Jun 2024 | gastric cancer | Jiuda Zhao | Unknown | No outcome recorded |
| Phase 2 | NCT05095467 | Oct 2021 → Oct 2023 overdue | gastric carcinoma, peritoneal carcinomatosis | Xuefei.Wang | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04515615 | Sep 2020 → Dec 2023 overdue | gastric cancer | Yu jiren | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03316326 | Nov 2017 → Dec 2021 | pancreatic ductal adenocarcinoma | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03267121 | Oct 2017 → Sep 2020 | head and neck squamous cell carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Completed | No outcome recorded |
| Phase 2 | NCT03096184 | Dec 2016 → Jul 2018 | head and neck squamous cell carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Unknown | No outcome recorded |
| Phase 2 | NCT01492543 | Dec 2011 → Apr 2014 | breast cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT00974389 | Jul 2009 → Jun 2010 | colorectal cancer | Osaka Medical College | Unknown | No outcome recorded |
| Phase 2 | NCT00994968 | Jul 2009 → ? | female breast carcinoma | Yonsei University | Unknown | No outcome recorded |
| Phase 2 | NCT00985556 | Jan 2009 → ? | gastric cancer | Yonsei University | Unknown | No outcome recorded |
| Phase 2 | NCT00659113 | Mar 2008 → ? | esophageal cancer | Yonsei University | Unknown | No outcome recorded |
| Phase 2 | NCT00625937 | Nov 2006 → Nov 2010 | head and neck cancer | Yonsei University | Unknown | No outcome recorded |
| Phase 2 | NCT00134095 | Sep 2004 → Aug 2008 | gastric cancer | Fukushima Medical University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00088816 | Apr 2003 → Mar 2008 | gastric cancer | Kyoto University | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04677673 | Jan 2021 → Jan 2022 overdue | chemotherapy-induced toxicity, gastric cancer | BIRENDRA KUMAR SAH | Not yet recruiting | No outcome recorded |
| Phase 35 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT04384601 | Sep 2021 → Sep 2022 overdue | gastric cancer | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT00660894 | Apr 2008 → Jun 2012 | colorectal cancer | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Completed | Met primary |
| Phase 3 | NCT00336947 | Apr 2006 → Mar 2012 | head and neck cancer | Yokohama City University | Unknown | Missed primary |
| Phase 3 | NCT00216034 | Mar 2005 → Feb 2016 | gastric cancer | Hokuriku-Kinki Immunochemotherapy Study Group | Completed | No outcome recorded |
| Phase 3 | NCT00182611 | Apr 2004 → Sep 2008 | gastric cancer | Kyoto University | Completed | No outcome recorded |
| Comparator or background therapy11 trials | ||||||
| Phase 0 | NCT07034742 Background | Jun 2025 → Jan 2026 overdue | gastric adenocarcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT05468138 Comparator | Aug 2022 → Dec 2025 | gastric adenocarcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04799548 Background | Dec 2021 → Dec 2024 | gastric cancer | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05122091 Background | Nov 2021 → Nov 2024 | gastric cancer, gastroesophageal cancer | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT03002831 Background | Nov 2016 → Oct 2019 | cancer of unknown primary site | Henan Cancer Hospital | Terminated | No outcome recorded |
| Phase 2/3 | NCT02746796 Background | Mar 2016 → Jan 2020 | gastric cancer | Ono Pharmaceutical Co., Ltd. | Completed | Mixed |
| Phase 3 | NCT07023315 Background | Aug 2025 → Jul 2029 expected | gastroesophageal adenocarcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 3 | NCT04997837 Background | Jul 2021 → Jul 2027 expected | gastric cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT03006705 Background | Jan 2017 → Aug 2022 | gastric cancer | Ono Pharmaceutical Co., Ltd. | Completed | Missed primary |
| Phase 3 | NCT03013010 Background | Dec 2016 → Dec 2024 | adenocarcinoma, gastric neoplasm, gastroesophageal cancer | Shanghai Cancer Hospital, China | Completed | No outcome recorded |
| Phase 3 | NCT00687843 Background | Jun 2008 → Mar 2016 | gastric cancer | Tokyo Metropolitan Oncology Group | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 38 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tegafur-gimeracil-oteracil potassium | “Tegafur gimeracil oteracil potassium capsules (40mg for body surface area \< 1.25/m\^2, 50mg/m\^2 for body surface area 1.25-1.5m\^2, 60mg for body surface area \> 1.5/m\^2)...” NCT05216237 ↗34“postoperative adjuvant chemotherapy with tislelizumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or tegafur-gimeracil-oteracil potassium +...” NCT06238167 ↗ “Intraperitoneal chemotherapy (fluorouracil + nab-paclitaxel + cisplatin + interleukin-2) PLUS systemic chemotherapy (SOX regimen: oxaliplatin + tegafur-gimeracil-oteracil potassium)” NCT07034742 ↗ “Drug: Tegafur-Gimeracil-Oteracil Potassium The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily” NCT05468138 ↗ “Day 1: Oxaliplatin 100mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 60mg/M2 oral” NCT04677673 ↗ “Tegafur gimeracil oteracil potassium capsule: 40-60mg bid（dosage according to body surface area）” NCT05122091 ↗ “A combination treatment made up of oxaliplatin and tegafur-gimeracil-oteracil potassium” NCT07023315 ↗ “Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily)” NCT04384601 ↗ “Oral Tegafur Gimeracil Oteracil Potassium Capsule 40-60 mg bid.” NCT04799548 ↗ “Tegafur gimeracil oteracil potassium capsule (TGO) 80mg/M2 oral” NCT04410887 ↗ |
| Known as | Aiyi | “Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule” NCT01492543 ↗ |
| Known as | S-1 | “Tegafur Gimeracil Oteracil Potassium Capsule is a novel oral derivative of the 5-fluorouracil(5-FU) prodrug tegafur combined with two modulators. Recent clinical trial has...” NCT01492543 ↗2“Adjuvant chemotherapy was administered as either tegafur-gimeracil-oteracil (S-1) at an initial dose of 40 mg/m2 per dose orally twice per day for 28 consecutive days, followed...” PMID 38906161 ↗ Jun 2024 “oral S-1 [tegafur-gimeracil-oteracil potassium] + oxaliplatin” PMID 39162872 ↗ Aug 2024 |
| Known as | TGO | “Tegafur gimeracil oteracil potassium capsule (TGO) 80mg/M2 oral” NCT04410887 ↗ |
| Modality | Small molecule | “an oral fluoropyrimidine S-1 alone” PMID 16803844 ↗ Jun 2006 |
| Route | Oral | “Patients receive oral S-1 on days 1-21” NCT00134095 ↗ |